Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)

CAMBRIDGE, Mass., Nov. 1, 2021 -- (Healthcare Sales & Marketing Network) --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercial... Biopharmaceuticals, Oncology, FDA Theseus Pharmaceuticals, targeted oncology, gastrointestinal stromal tumors
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news